30th
EASDec
Annual Meeting

5th – 6th November 2020
Barcelona (Spain)

Scientific Programme

VIRTUAL FORMAT

EASD
Eye Complications Study Group

SCIENTIFIC PROGRAMME

VIRTUAL FORMAT

THURSDAY, 5th NOVEMBER 2020

15.00: Satellite Symposium 1

Symposium Bayer

Update and controversies on the treatment of DR and DME

Welcome and Introduction (Chair)
Prof. Rafael Simó (Spain)

Aflibercept: Optimizing Anti-VEGF Therapy in Retinal Disease
Dr. Patricia Udaondo (Spain)

Controversies in DR and DME: Importance of Early, Intensive Treatment
Dr. Olga Simó-Servat (Spain)

EURETINA Guidelines and RWE
Dr. Lluís Arias (Spain)

16.30: Break

17:00 Satellite Symposium 2

Diabetic retinopathy as a biomarker of cardiovascular disease

Symposium Novo Nordisk

Welcome and introduction (Chair)
Prof. Javier Escalada (Spain)

The influence of microangiopathy on macroangiopathy in diabetes
Prof. Dídac Mauricio (Spain)

Diabetic retinopathy as a risk factor of cardiovascular disease
Prof. Rafael Simó (Spain)

The role of microangiopathy in heart failure
Prof. Vivencio Barrios (Spain)

FRIDAY, 6th NOVEMBER 2020

09:00   INTRODUCTION AND WELCOME

Prof. Rafael Simó (Spain)

9:10 ORAL COMMUNICATIONS: Basic and translational research in diabetic eye complications

(Supported by Mundipharma)

Chair: Prof. Alan Stitt (UK)

9:12-9:20 Patrice Fort (Michigan, US)
Regional changes of retinal physiology in humans: diabetes vs retinopathy

9:20-9:28 Esmeralda Bosma (Netherlands)
The role of eNOS in VEGF-induced vascular permeability

9:28-9:36 Olga Simó-Servat (Spain)
ERM complex, a therapeutic target for vascular leakage induced by diabetes

9:36-9:44 Hugo Ramos (Spain)
DPP-IV inhibitors for treating early stages of diabetic retinopathy in an experimental model: a dose-efficacy study

9:44-9:52 Tine Van Bergen (Belgium)
Targeting plasma kallikrein with a novel bicyclic peptide inhibitor (THR-149) reduces retinal thickening in a diabetic rat model

9:52-10:00 Eleni Beli (UK)
Diurnal rhythms of myeloid cell infiltration into the retina in type 1 diabetes (T1D)

10:00-10:15 Break

10:15 SESSION: Screening of diabetic retinopathy in Europe: current status and new challenges

Chair: Prof. Peter Scanlon (UK)

10:16-10:24 Katie Hazelgrove (UK)
Incidence of referable diabetic retinopathy at patient's first screening

10:24-10:32 Jacob Grauslund (Denmark)
Identification and characterization of patients with rapid progression of diabetic retinopathy in the Danish national screening program

10:32-10:40 Deborah M. Broadbent (UK)
Safety, efficacy and cost effectiveness of individual screening for diabetic retinopathy: the Individualised Screening for Diabetic Retinopathy (ISDR) single centre, open label, equivalence randomised controlled trial

10:40-10:48 Rajiv Pandey (Ireland)
Irish National Diabetic Retina Screen programme: 5 rounds of screening and referrals

10:48-10:56 Caroline Styles (UK)
Use of dilating drops in the Scottish Diabetic Retinopathy Screening Programme

10:56-11:04 Jonathan Pons (Eswatini)
Establishing a diabetic retinopathy screening service in Eswatini

11:04-11:12 Naiara Relaño-Barambio (Spain)
Validation of a deep learning algorithm for diabetic retinopathy

11:12-11:20 Frank Verbraak (Netherlands)
Validation of automated screening for referable diabetic retinopathy with an automatic device (IDxDR) in a Spanish population

11:20-11:30 Break

11:30 *SHORT TALK PRESENTATIONS*

Experimental research
Chair: Dr. Cristina Hernández (Spain)

11:30-11:35 – Aurora Mazzeo (Italy)
Effects of melanocortin receptor agonism in cell models of the inner blood-retinal barrier cultured in diabetic-like conditions

11:35-11:40 – Natasha Varsney (UK)
Fluctuating hyperglycaemia has the same effect as sustained hyperglycaemia in an in vitro model of diabetic retinopathy

11:40-11:45 – Ana I. Arroba (Spain)
Anti-inflammatory (m2) response is induced by a synthetic glycolipid-type molecule ((1r)-1-dodecylsulfinyl-5N, 6O-oxomethylidenenojirimycin): a new possible treatment in diabetic retinopathy

11:45-11:50 – Ingeborg Klaassen (Netherlands)
Involvement of PDGF in neurite outgrowth leading to fibrovascular membranes in PDR

Screening and epidemiology
Chair: Dr. Deborah M. Broadbent

11:55-12:00– Henrik Lund-Andersen (Denmark)
Prevalence of diabetic retinopathy in Greenland

12:00-12:05 – Jayashree Sahni (California, US)
Insights into progression of diabetic retinopathy (DR) severity among primary care patients with diabetes in the United States

12:05-12:10 – Angela Dale (UK)
The use of virtual clinics to manage diabetic retinopathy patients with delayed follow up appointments in an English hospital eye service

12:10-12:15 – Catherine Jamison (UK)
Diabetic eye disease in patients with diabetes mellitus secondary to chronic pancreatitis (DMsCP)

Retinal imaging and artificial intelligence

Chair: Prof. Frank D. Verbraak

12:20- 12:25 – Rosangela Lattanzio (Italy)
MultiColor imaging to detect different subtypes of retinal microaneurysms in diabetic retinopathy

12:25-12:30 – Andreea Ciudin (Spain)
Retinal sensitivity and gaze fixation: two independent and valuable measurments that could be obtained by using microperimetry

12:30-12:35 – Georgios Bontzos (Greece)
Retinal neurodegeneration, macular circulation and morphology of the foveal avascular zone in diabetic patients. Quantitative cross-sectional study using OCT-A

12:35-12:40 – Mariacristina Parravano (Italy)
Deep capillary plexus impairment as a biomarker of diabetic retinopathy progression in the long-term follow up in type 1 diabetes

Diabetic retinopathy treatment
Chair: Dr. Rosangela Lattanzio

12:45-12:50 – Irene Stratton (UK)
Outcomes in patients with diabetic macular oedema treated with aflibercept for up to three years

12:50-12:55 – Søren Leer Blindbæk (Denmark)
Changes in retinal microvasculature parameters after low-carbohydrate, high-fat diet in type 2 diabetes: a randomized-controlled trial of Danish type 2 diabetic patients

12:55-13:00 – Anna Stage Vergmann (Denmark)
Retinal vascular oxygen saturation in response to panretinal photocoagulation in proliferative diabetic retinopathy: detection of a dose-response relationship?

13:0-13:05 – Diana Minasyan (Ireland)
Evaluation of real-life clinical outcomes of intravitreal anti-VEGF injections for diabetic maculopathy in Diabetic Retina Treatment Unit, Mater Misericordiae University Hospital, Dublin, Ireland

13:10-14:00 LUNCH + POSTER SESSION 1 (See Annex)

14:00 ORAL COMMUNICATIONS: Clinical management and treatment of diabetic eye complications

Chair: Prof. Patrice Fort (USA)

14:00-14:08 Rafael Simó (Spain)
Diabetic retinopathy as an independent predictor of subclinical cardiovascular disease: baseline results of the PRECISED study

14:08-14:16 Kiran Shah (India)
Diabetic retinopathy grade as predictor of outcomes in patients with type 2 diabetes and lower extremity amputations – multicentric longitudinal seven years study

14:16-14:24 José Cunha-Vaz (Portugal)
Ocular and systemic risk markers of diabetic retinopathy progression. A five-year longitudinal study

14:24-14:32 Inês Pereira Marques (Portugal)
Different retinopathy phenotypes in diabetes type 2 show different five-year risks for development of DME and PDR

14:32-14:40 Reinier Schlingemann (Netherlands)
miRNA levels as a biomarker for anti-VEGF response in patients with diabetic macular edema

14:40-14:48 Qian Yang (UK)
Retinal vasculature damage in the deeper plexus is more severe than in the superficial plexus during very early diabetic retinopathy

14:50-15:00 Break

15:00 ROUND TABLE: *Looking at retinal neurodegeneration and beyond*

(Supported by OM-VIFOR PHARMA)

Chair: Prof. Jakob Grauslund (Denmark)

- The neurovascular unit: a key element in the development of vascular leakage
  Alan Stitt (UK)
- Retinal neurodegeneration in diabetes: clinical and therapeutic implications.
  Rafael Simó (Spain)
- Retinal fingerprint of neurodegenerative diseases
  Frank D. Verbraak (Netherlands)

16:20 SESSION: "Liquid biopsy: usefulness for personalized treatment in DME"

(Supported by ROCHE)

Chair: Dr. Patricia Udaondo (Spain)

- Retinal disease phenotyping through advanced ocular omics
  Andreas Dieckmann (Switzerland)
- Personalized medicine by targeting pro-inflammatory cytokines in DR and DME
  Marina Mesquida (Switzerland)

17:20 SESSION: "What should know the GP about DR?"

(Supported by AstraZeneca)

Chair: Dr. Maria Cristina Parravano (Italy) and Dr. Xavier Mundet (Spain)

- Relationship with other diabetic complications
  Manel Mata (Spain)
- Can DR influence the management of diabetes?
  Olga Simó-Servat (Spain)

18:15-19:25 POSTER SESSION 2 (18:15-18:45) and 3 (18:55-19:25). Please see Annex

19:30 ANNUAL GENERAL MEETING, PRESENTATION OF NEXT EASDEC MEETING AND FAREWELL

The Board: Rafael Simó (president), Tunde Peto (vice-president), Reinier Schlingemann (treasurer), Stela Vujosevic (secretary), Simon Harding (past-president).

Organizer of the next EASDec meeting: Jakob Grauslund

ANNEX

POSTER SESSION 1 (Screening and epidemiology: 13:15-13:45)

Chair: Tunde Peto (UK)

1 – Steve Aldington (UK)
International students undertaking UK University-validated distance-learning courses in Diabetic Retinopathy Screening (DRS)

2 – Rosalind Creer (UK)
Assessing virtual clinic quality and safety for patients with diabetic eye disease at Manchester Royal Eye Hospital

3 – Iona Minty (UK)
Incidental vascular findings in diabetic eye screening: do patients benefit from referral?

4 – Robert Rehak (UK)
Profile, visual and maculopathy outcomes of patients referred for the first time with pre-proliferative diabetic retinopathy from screening into a hospital eye service

5 – Martina Tomić (Croatia)
Association between homocysteine and the risk of retinopathy in type 2 diabetes

6 – Donal McCullagh (UK)
Audit of referral of patients graded as R3 (proliferative retinopathy) by diabetic eye screening programme Northern Ireland (DESPNI)

7 – Laura Cushley (UK)
Certification of Visual Impairment in Patients with Diabetes Mellitus in Northern Ireland over a 5 year period

8 – Laura Kennelly (Ireland)
Irish Diabetic Retinopathy Screening Programme: An analysis of grade R2 screened patients in 2015

9 – Alan Sproule (UK)
Grading data are only as good as the graders – and all data depends on good quality questions

10 – Tunde Peto (UK)
Young people's view of Diabetic Retinopathy Screening in Northern Ireland

POSTER SESSION 2 (Retinal imaging and artificial intelligence: 18:15-18:45)

Chair: Simon Harding (UK)

1 – Giuseppe Querques (Italy)
Nonmydriatic widefield retinal imaging with an automatic white LED confocal imaging system compared with dilated ophthalmoscopy in screening for diabetic retinopathy

2 – Maria Luisa Ribeiro (Portugal)
Baseline characterization of retinal vascular disease in eyes with mild to moderate non proliferative diabetic retinopathy (NPDR) in diabetes type 2, using novel non-invasive Imaging methods, in a longitudinal, prospective and interventional 2-year clinical study (CORDIS)

3 – Maribel Lopez (Spain)
Automated diabetic retinopathy quality image assessment: diagnostic accuracy in clinical practice

4 – Lars Díaz (Denmark)
Neural networks and left/right classification of retinal images

5 – Fethallah Benmansour (Switzerland)
Machine Learning to Predict Diabetic Retinopathy Improvement in Patients with Mild NPDR Using Systemic and Retinal Imaging Features

6 – Jacob Andersen (Denmark)
Using Semantic Segmentation for Detection of Microaneurysms in Retinal Images

7 – Thomas Lee Torp (Denmark)
Validation of the SIVA-plus deep-learning algorithm on retinal vascular calibre in patients with treatment-naïve proliferative diabetic retinopathy before and after panretinal photocoagulation

8 – Kim Gooding (UK)
Examining the impact of type 2 diabetes on longitudinal changes in fovea thickness

9 – Andrzej Grzybowski (Poland)
Pilot artificial intelligence based diabetic retinopathy screening programme in Poland

10 – Marie Torm (Denmark)
Hyperreflective dots on optical coherence tomography scans of diabetic retinopathy – can some of them represent non-perfused capillaries?

11 – Romano Vrabec (Croatia)
Association between retinal nerve fiber layer, ganglion cell layer with inner plexiform layer and diabetic retinopathy in type 2 diabetes

POSTER SESSION 3 (Diabetic retinopathy treatment 18:55-19:25)

Chair: Reinier Schlingemann (Netherlands)

1 – Valeriya A. Biletskaya (Russia)
Neovascular glaucoma drainage surgery, remote results for diabetic patients.

2 – Eylem Cagiltay (Turkey)
Optical coherence tomography biomarkers to predict anti-VEGF response in diabetic macular edema

3 – Emine Doğan (Turkey)
Short term effects of intravitreal Bevacizumab injection on retinal nerve fiber layer thickness

4 – Mehmet Murat Uzel (Turkey)
Prognostic value of subretinal fluid volume in patients with Ranibizumab-resistant diabetic macular edema treated with intravitreal Dexamethasone

5 – Stela Vujosevic (Italy)
Subthreshold micropulse laser in diabetic macular edema: OCT and OCT-Angiography biomarkers of treatment response

6 – Irina Bashina (Russia)
The use of prolonged corticosteroids for the prevention of macular edema after cataract surgery in patients with diabetes mellitus

7 – Mehmed Uğur Işik (Turkey)
Investigation of choroidal thickness changes after intravitreal Bevacizumab treatment in the treatment of diabetic macular edema

8 – Lazaros Konstantinidis (Switzerland)
Outcomes of hybrid mixed-gauge by bimanual vitrectomy for diabetic tractional retinal detachment

9 – Ernest Lim (UK)
Short-term effectiveness of subthreshold laser therapy for predominantly non-centre involving diabetic macular oedema

MAIN SPONSORS

BAYER

novo nordisk®

OM PHARMA
A Vifor Pharma Group Company

SPONSORS

AstraZeneca

mundipharma

Roche

icare
For better perception

OPTOMED

optos®

SECRETARIAT CONGRESS

Gòtic

Tel. + 34 93 317 8444 - + 34 626 214 273
gotic@gotic-congres.com • www.gotic-congres.com

Vall d'Hebron
Barcelona Campus Hospitalari

Vall d'Hebron
Institut de Recerca